131 related articles for article (PubMed ID: 38205742)
1. Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: Evidence from Canada.
Regier DA; Loewen R; Chan B; Ehman M; Pollard S; Friedman JM; Stockler-Ipsiroglu S; van Karnebeek C; Race S; Elliott AM; Dragojlovic N; Lynd LD; Weymann D
Genet Med; 2024 Apr; 26(4):101069. PubMed ID: 38205742
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.
Lavelle TA; Feng X; Keisler M; Cohen JT; Neumann PJ; Prichard D; Schroeder BE; Salyakina D; Espinal PS; Weidner SB; Maron JL
Genet Med; 2022 Jun; 24(6):1349-1361. PubMed ID: 35396982
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies.
Li C; Vandersluis S; Holubowich C; Ungar WJ; Goh ES; Boycott KM; Sikich N; Dhalla I; Ng V
Genet Med; 2021 Mar; 23(3):451-460. PubMed ID: 33110268
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(11):1-178. PubMed ID: 32194879
[TBL] [Abstract][Full Text] [Related]
5. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study.
Dragojlovic N; Elliott AM; Adam S; van Karnebeek C; Lehman A; Mwenifumbo JC; Nelson TN; du Souich C; Friedman JM; Lynd LD
Genet Med; 2018 Sep; 20(9):1013-1021. PubMed ID: 29300375
[TBL] [Abstract][Full Text] [Related]
6. The performance of genome sequencing as a first-tier test for neurodevelopmental disorders.
van der Sanden BPGH; Schobers G; Corominas Galbany J; Koolen DA; Sinnema M; van Reeuwijk J; Stumpel CTRM; Kleefstra T; de Vries BBA; Ruiterkamp-Versteeg M; Leijsten N; Kwint M; Derks R; Swinkels H; den Ouden A; Pfundt R; Rinne T; de Leeuw N; Stegmann AP; Stevens SJ; van den Wijngaard A; Brunner HG; Yntema HG; Gilissen C; Nelen MR; Vissers LELM
Eur J Hum Genet; 2023 Jan; 31(1):81-88. PubMed ID: 36114283
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods.
Ferket BS; Baldwin Z; Murali P; Pai A; Mittendorf KF; Russell HV; Chen F; Lynch FL; Lich KH; Hindorff LA; Savich R; Slavotinek A; Smith HS; Gelb BD; Veenstra DL
Genet Med; 2022 Oct; 24(10):2014-2027. PubMed ID: 35833928
[TBL] [Abstract][Full Text] [Related]
8. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders.
Dragojlovic N; van Karnebeek CDM; Ghani A; Genereaux D; Kim E; Birch P; ; Elliott AM; Friedman JM; Lynd LD
Genet Med; 2020 Feb; 22(2):292-300. PubMed ID: 31462755
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder.
Yuen T; Carter MT; Szatmari P; Ungar WJ
Appl Health Econ Health Policy; 2018 Aug; 16(4):481-493. PubMed ID: 29651777
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Whole-Genome vs Whole-Exome Sequencing Among Children With Suspected Genetic Disorders.
Nurchis MC; Radio FC; Salmasi L; Heidar Alizadeh A; Raspolini GM; Altamura G; Tartaglia M; Dallapiccola B; Pizzo E; Gianino MM; Damiani G
JAMA Netw Open; 2024 Jan; 7(1):e2353514. PubMed ID: 38277144
[TBL] [Abstract][Full Text] [Related]
11. Narrowing the diagnostic gap: Genomes, episignatures, long-read sequencing, and health economic analyses in an exome-negative intellectual disability cohort.
Dias KR; Shrestha R; Schofield D; Evans CA; O'Heir E; Zhu Y; Zhang F; Standen K; Weisburd B; Stenton SL; Sanchis-Juan A; Brand H; Talkowski ME; Ma A; Ghedia S; Wilson M; Sandaradura SA; Smith J; Kamien B; Turner A; Bakshi M; Adès LC; Mowat D; Regan M; McGillivray G; Savarirayan R; White SM; Tan TY; Stark Z; Brown NJ; Pérez-Jurado LA; Krzesinski E; Hunter MF; Akesson L; Fennell AP; Yeung A; Boughtwood T; Ewans LJ; Kerkhof J; Lucas C; Carey L; French H; Rapadas M; Stevanovski I; Deveson IW; Cliffe C; Elakis G; Kirk EP; Dudding-Byth T; Fletcher J; Walsh R; Corbett MA; Kroes T; Gecz J; Meldrum C; Cliffe S; Wall M; Lunke S; North K; Amor DJ; Field M; Sadikovic B; Buckley MF; O'Donnell-Luria A; Roscioli T
Genet Med; 2024 May; 26(5):101076. PubMed ID: 38258669
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the diagnostic and clinical utility of exome and genome sequencing in pediatric and adult patients with rare diseases across diverse populations.
Chung CCY; Hue SPY; Ng NYT; Doong PHL; ; Chu ATW; Chung BHY
Genet Med; 2023 Sep; 25(9):100896. PubMed ID: 37191093
[TBL] [Abstract][Full Text] [Related]
13. Evidence from 2100 index cases supports genome sequencing as a first-tier genetic test.
Guo F; Liu R; Pan Y; Collins C; Bean L; Ma Z; Mathur A; Da Silva C; Nallamilli B; Guruju N; Chen-Deutsch X; Yousaf R; Chin E; Balciuniene J; Hegde M
Genet Med; 2024 Jan; 26(1):100995. PubMed ID: 37838930
[TBL] [Abstract][Full Text] [Related]
14. Clinical genome sequencing: Three years' experience at a tertiary children's hospital.
Kumar RD; Saba LF; Streff H; Shaw CA; Mizerik E; Snyder MT; Lopez-Terrada D; Scull J
Genet Med; 2023 Oct; 25(10):100916. PubMed ID: 37334785
[TBL] [Abstract][Full Text] [Related]
15. Exome sequencing as first-tier genetic testing in infantile-onset pharmacoresistant epilepsy: diagnostic yield and treatment impact.
Boonsimma P; Ittiwut C; Kamolvisit W; Ittiwut R; Chetruengchai W; Phokaew C; Srichonthong C; Poonmaksatit S; Desudchit T; Suphapeetiporn K; Shotelersuk V
Eur J Hum Genet; 2023 Feb; 31(2):179-187. PubMed ID: 36198807
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases.
Incerti D; Xu XM; Chou JW; Gonzaludo N; Belmont JW; Schroeder BE
Genet Med; 2022 Jan; 24(1):109-118. PubMed ID: 34906478
[TBL] [Abstract][Full Text] [Related]
17. Interest of exome sequencing trio-like strategy based on pooled parental DNA for diagnosis and translational research in rare diseases.
Tran Mau-Them F; Duffourd Y; Vitobello A; Bruel AL; Denommé-Pichon AS; Nambot S; Delanne J; Moutton S; Sorlin A; ; Couturier V; Bourgeois V; Chevarin M; Poe C; Mosca-Boidron AL; Callier P; Safraou H; Faivre L; Philippe C; Thauvin-Robinet C
Mol Genet Genomic Med; 2021 Dec; 9(12):e1836. PubMed ID: 34716697
[TBL] [Abstract][Full Text] [Related]
18. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness.
Palmer EE; Schofield D; Shrestha R; Kandula T; Macintosh R; Lawson JA; Andrews I; Sampaio H; Johnson AM; Farrar MA; Cardamone M; Mowat D; Elakis G; Lo W; Zhu Y; Ying K; Morris P; Tao J; Dias KR; Buckley M; Dinger ME; Cowley MJ; Roscioli T; Kirk EP; Bye A; Sachdev RK
Mol Genet Genomic Med; 2018 Mar; 6(2):186-199. PubMed ID: 29314763
[TBL] [Abstract][Full Text] [Related]
19. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).
Manickam K; McClain MR; Demmer LA; Biswas S; Kearney HM; Malinowski J; Massingham LJ; Miller D; Yu TW; Hisama FM;
Genet Med; 2021 Nov; 23(11):2029-2037. PubMed ID: 34211152
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients.
Yeung A; Tan NB; Tan TY; Stark Z; Brown N; Hunter MF; Delatycki M; Stutterd C; Savarirayan R; Mcgillivray G; Stapleton R; Kumble S; Downie L; Regan M; Lunke S; Chong B; Phelan D; Brett GR; Jarmolowicz A; Prawer Y; Valente G; Smagarinsky Y; Martyn M; McEwan C; Goranitis I; Gaff C; White SM
Genet Med; 2020 Dec; 22(12):1986-1993. PubMed ID: 32773771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
